MedPath

Eli Lilly Nederland BV

🇳🇱Netherlands
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.lilly.com/nl

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

80

NMPA:55
EMA:25

Drug Approvals

Tirzepatide Injection

Product Name
穆峰达
Approval Number
国药准字HJ20255005
Approval Date
Apr 29, 2025
NMPA

Tirzepatide Injection

Product Name
穆峰达
Approval Number
国药准字HJ20255007
Approval Date
Apr 29, 2025
NMPA

Tirzepatide Injection

Product Name
穆峰达
Approval Number
国药准字HJ20255004
Approval Date
Apr 29, 2025
NMPA

Tirzepatide Injection

Product Name
穆峰达
Approval Number
国药准字HJ20255006
Approval Date
Apr 29, 2025
NMPA

Pemetrexed Disodium for Injection

Product Name
力比泰
Approval Number
国药准字HJ20150445
Approval Date
Nov 26, 2024
NMPA

Pemetrexed Disodium for Injection

Product Name
力比泰
Approval Number
国药准字HJ20140662
Approval Date
Nov 26, 2024
NMPA

Pirtobrutinib Tablets

Product Name
捷帕力
Approval Number
国药准字HJ20240116
Approval Date
Oct 22, 2024
NMPA

Pirtobrutinib Tablets

Product Name
捷帕力
Approval Number
国药准字HJ20240117
Approval Date
Oct 22, 2024
NMPA

Teriparatide Injection

Product Name
复泰奥
Approval Number
国药准字SJ20170032
Approval Date
Sep 10, 2024
NMPA

Tirzepatide Injection

Product Name
穆峰达
Approval Number
国药准字HJ20240021
Approval Date
Jul 23, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)
No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath